Telehorse SA (Cannabis Poland) (“Issuer”) informs that on 16/07/2019 the Management signed copy of the “Agreement of cooperation” with „Promotorzy Trading Sp. z o.o.” with its registered office in Warsaw
(“Partner”).

Cooperation with the Partner includes:
1) implementation of Research
& Development works, and production under the Issuer’s own brands of
vaporizing liquids with the main focus on products containing
cannabinoids;
2) import of equipment for vaporization and
accessories – also for medical purposes – under the Issuer’s own brands;
3) distribution of the above-mentioned products
through the Partner’s channels.The
contract is concluded for an indefinite period with a three-month
notice.Partner operates in the industry of production and distribution
of tobacco products and accessories as well as e-cigarettes and liquids.
The Partner’s portfolio is today the widest and most complete in Poland,
and its areas of activity include production, import, export and
distribution in 11,000 stores in Poland and abroad. The Partner also has
its own research and development department (“R & D”).The
Issuer indicates that after changing the name to ‘Cannabis Poland’, it
will be conducting business in the production and sale of pharmaceutical
and medical products with a focus on vaporizing products containing
cannabinoids made from hemp. Vaporizing rich in cannabinoids is
considered the most effective, effective and economical method of taking
cannabinoids.Cannabinoids are used in anti-inflammatory, analgesic,
anxiolytic, antipsychotic and antispasmodic cures. They are used in
Alzheimer’s and Parkinson’s diseases, sclerosis, leukemia, diabetes,
asthma, epilepsy, spinal cord injuries, migraines, and withdrawal
therapies. They help with rheumatic pains, and have antiemetic and
appetite stimulating properties, which is essential for people during
chemotherapy. They can also be used in the process of rehab while
fighting the addiction of smoking and heroin. Cannabinoids are also used
to treat drug-resistant epilepsy.

The size of the medical market, based on cannabis, is
estimated in 2028 in Poland at EUR 2 billion and at EUR 58 billion
throughout Europe.